BRPI0818324A2 - formulações líquidas de lh - Google Patents

formulações líquidas de lh

Info

Publication number
BRPI0818324A2
BRPI0818324A2 BRPI0818324A BRPI0818324A BRPI0818324A2 BR PI0818324 A2 BRPI0818324 A2 BR PI0818324A2 BR PI0818324 A BRPI0818324 A BR PI0818324A BR PI0818324 A BRPI0818324 A BR PI0818324A BR PI0818324 A2 BRPI0818324 A2 BR PI0818324A2
Authority
BR
Brazil
Prior art keywords
liquid formulations
formulations
liquid
Prior art date
Application number
BRPI0818324A
Other languages
English (en)
Inventor
Del Rio Alessandra
Samaritani Fabrizio
Richard Joel
Agostinetto Rita
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of BRPI0818324A2 publication Critical patent/BRPI0818324A2/pt
Publication of BRPI0818324B1 publication Critical patent/BRPI0818324B1/pt
Publication of BRPI0818324B8 publication Critical patent/BRPI0818324B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0818324A 2007-11-01 2008-10-29 formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica BRPI0818324B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
US448107P 2007-11-28 2007-11-28
PCT/EP2008/064679 WO2009056569A1 (en) 2007-11-01 2008-10-29 Lh liquid formulations

Publications (3)

Publication Number Publication Date
BRPI0818324A2 true BRPI0818324A2 (pt) 2017-05-16
BRPI0818324B1 BRPI0818324B1 (pt) 2019-12-24
BRPI0818324B8 BRPI0818324B8 (pt) 2021-05-25

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818324A BRPI0818324B8 (pt) 2007-11-01 2008-10-29 formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica

Country Status (26)

Country Link
US (1) US8664369B2 (pt)
EP (1) EP2219607B1 (pt)
JP (1) JP5551601B2 (pt)
KR (1) KR101513181B1 (pt)
CN (1) CN101842083B (pt)
AU (1) AU2008320844B2 (pt)
BR (1) BRPI0818324B8 (pt)
CA (1) CA2700662C (pt)
CY (1) CY1113121T1 (pt)
DK (1) DK2219607T3 (pt)
EA (1) EA019432B1 (pt)
EC (1) ECSP10010224A (pt)
ES (1) ES2393233T3 (pt)
HK (1) HK1145443A1 (pt)
HR (1) HRP20120660T1 (pt)
IL (1) IL205105A (pt)
MX (1) MX2010004639A (pt)
MY (1) MY153976A (pt)
NZ (1) NZ583991A (pt)
PL (1) PL2219607T3 (pt)
PT (1) PT2219607E (pt)
RS (1) RS52566B (pt)
SI (1) SI2219607T1 (pt)
UA (1) UA101484C2 (pt)
WO (1) WO2009056569A1 (pt)
ZA (1) ZA201001907B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2229407B1 (de) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
JP5735960B2 (ja) * 2009-07-06 2015-06-17 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング メチオニンを含むインスリン製剤
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
WO2011058082A1 (de) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
WO2011099036A2 (en) * 2010-02-12 2011-08-18 Intas Biopharmaceuticals Limited Liquid formulation of follicle stimulating hormone
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2014102623A1 (en) * 2012-12-26 2014-07-03 Wockhardt Limited Pharmaceutical composition
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
PL3229828T3 (pl) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
AU707796B2 (en) * 1995-03-21 1999-07-22 Merck Serono Sa HCG liquid formulations
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
EP2174663A1 (en) * 2003-01-08 2010-04-14 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (TFPI) or tissue factor pathway inhibitor variant
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant

Also Published As

Publication number Publication date
ES2393233T3 (es) 2012-12-19
UA101484C2 (en) 2013-04-10
JP5551601B2 (ja) 2014-07-16
WO2009056569A9 (en) 2010-01-21
SI2219607T1 (sl) 2012-09-28
CN101842083A (zh) 2010-09-22
US20100261649A1 (en) 2010-10-14
PL2219607T3 (pl) 2012-12-31
CN101842083B (zh) 2012-11-14
US8664369B2 (en) 2014-03-04
EA201070549A1 (ru) 2010-10-29
MY153976A (en) 2015-04-30
AU2008320844B2 (en) 2013-08-29
AU2008320844A1 (en) 2009-05-07
WO2009056569A1 (en) 2009-05-07
EA019432B1 (ru) 2014-03-31
JP2011502968A (ja) 2011-01-27
KR101513181B1 (ko) 2015-04-21
CA2700662A1 (en) 2009-05-07
ZA201001907B (en) 2011-05-25
BRPI0818324B8 (pt) 2021-05-25
CY1113121T1 (el) 2016-04-13
RS52566B (en) 2013-04-30
IL205105A (en) 2015-04-30
NZ583991A (en) 2012-02-24
EP2219607B1 (en) 2012-08-15
BRPI0818324B1 (pt) 2019-12-24
HK1145443A1 (en) 2011-04-21
IL205105A0 (en) 2010-11-30
KR20100088147A (ko) 2010-08-06
ECSP10010224A (es) 2010-07-30
CA2700662C (en) 2015-10-13
PT2219607E (pt) 2012-08-31
MX2010004639A (es) 2010-08-04
DK2219607T3 (da) 2013-06-17
HRP20120660T1 (hr) 2012-09-30
EP2219607A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
BRPI0818324A2 (pt) formulações líquidas de lh
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0818380A2 (pt) Combinação de herbicida-protetor
BRPI0909644A2 (pt) dispositivo de foto-epilação
BRPI0814324A2 (pt) Dispositivo
BRPI0822034A2 (pt) Dispositivo
DK2114143T3 (da) Flydende sulfonylurea-herbicidformuleringer
DK2789349T3 (da) Flydende præparat omfattende pimobendan
BRPI0814188A2 (pt) Formulações
BRPI0813976A2 (pt) Separador de líquido
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona
BRPI0821224A2 (pt) Filtro de líquido
DE602007000495D1 (de) Flüssigkeit-Koinfusionsgerät
DK2196587T3 (da) Afløbsindretning
BRPI0906734A2 (pt) Dispositivo de virola
BRPI0817518A2 (pt) Dispositivo de acoplamento
DE502008001742D1 (de) Kabelbearbeitungseinrichtung
BRPI0809653A2 (pt) Formulações líquidas de manoproteína
BRPI0816109A2 (pt) Separador de líquido
FIU20090163U0 (fi) Kaavinlaite
BRPI0810835A2 (pt) Formulações de hidroquinona ansamicina
DE602008000633D1 (de) Wischvorrichtung
UY33138A (es) Formulaciones liquidas
ITVA20070044U1 (it) Abbracciatovagliolo - abbraccia tovagliolo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF